Home Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment
 

Keywords :   


Gurnet Point Capital Launches New Drug Development Company, Boston Pharmaceuticals, With $600M Commitment

2015-11-20 04:25:37| drugdiscoveryonline Home Page

Gurnet Point Capital, an investment firm focused on the healthcare and life sciences sectors that was founded by Ernesto Bertarelli and is led by Christopher A. Viehbacher, recently announced the creation of Boston Pharmaceuticals, a fully-integrated drug development company that will offer an innovative alternative model for drug development and commercialization.

Tags: company point development capital

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 9
05.11Tropical Storm Rafael Wind Speed Probabilities Number 9
05.11Tropical Storm Rafael Public Advisory Number 9
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Forecast Advisory Number 9
05.11Kim Madigan to chair 2025 FTA Fall Technical Conference
05.11PM responds to Sir Alan Bates after repeated requests
More »